Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

HEPANOVA: a Phase II Trial of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Sorafenib for Advanced Hepatocellular Carcinoma (HCC)

NCT03606590 is registered in ClinicalTrials.gov with NovoCure Ltd. as lead sponsor.

NCT NCT03606590
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03606590 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
HEPANOVA: a Phase II Trial of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Sorafenib for Advanced Hepatocellular Carcinoma (HCC)
Lead sponsor
NovoCure Ltd.
Phase
Phase 2
Overall status
Completed
Start date
February 15, 2019
Completion date
January 14, 2021
Enrollment
25 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma